Notably, when IDH1/2 is mutated, the enzyme catalyzes α-KG to generate the oncogenic metabolite D-2-hydroxyglutarate (D-2HG), despite the very low frequency of IDH mutations in colorectal cancer, studies have demonstrated that D-2HG administration during colitis delays colitis resolution and accelerates tumorigenesis (326). The gene discussed is IDH2; the disease is colitis.